ペプチドCDMOサービスの世界市場レポート2025-2031
英文タイトル: Global Peptide CDMO Services Market Insights, Forecast to 2031
販売価格(消費税別)
個人版
マルチユーザー版
企業版
価格表記: USDを日本円(税抜)に換算,本日の銀行送金レート: 1USD=149.50円。
※米ドル表示価格+10%消費税。
価格表記: USDを日本円(税抜)に換算,本日の銀行送金レート: 1USD=149.50円。
※米ドル表示価格+10%消費税。
※ご注文方法:お問い合わせフォームまたはメールにてご連絡ください。
支払方法:「銀行振込」の場合, 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期:原則として、受注後2~4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8~10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。
概要
本報告書は、ペプチドCDMOサービスの世界市場、容量、生産量、収益、価格の概要を紹介します。2020~2024年の歴史的な市場収益/売上データ、2025年の予想、および2031年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別にペプチドCDMOサービス市場を分類しています。本レポートでは世界のペプチドCDMOサービス市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は:Bachem、PolyPeptide、CordenPharma、AmbioPharm、USV Peptides、Thermofischer、Bio Basic、JPT、Genscript、Xinbang Pharma、ScinoPharm、SN Biopharm、CBL、Piramal Pharma、CPC Scientific
レポートはペプチドCDMOサービスの主要生産者を調査し、主要地域や国の消費状況も提供します。ペプチドCDMOサービスの今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。
2020年から2031年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。タイプ別市場セグメント:
一. 生産面では、2020年から2025年まで、そして2031年までの予測として、メーカー別、地域別(地域レベル、国レベル)のペプチドCDMOサービス生産量、成長率、市場シェアを調査している。
APIs and Intermediates
FDF
用途別の市場セグメント:
Commercial
Academic Research
Other
本レポートの詳細内容
本レポートは、世界のペプチドCDMOサービス市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいてペプチドCDMOサービス市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
二. 消費面では、ペプチドCDMOサービスの売上高を地域別(地域レベル・国レベル)、企業別、種類別、用途別に焦点を当てています。2020年から2025年まで、2031年までの予測。
三.主要メーカーのペプチドCDMOサービス売上高、収益、市場シェア、業界ランキング、2020年から2025年までのデータに焦点を当てています。世界のペプチドCDMOサービス市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。
四.本ペプチドCDMOサービスのレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。
章の概要第1章:ペプチドCDMOサービスのレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー(タイプ別およびアプリケーション別など)を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。(2020~2031)
第2章: ペプチドCDMOサービスの世界と主要生産者(地域/国)の生産/アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。(2020~2031)
第3章:世界、地域、国レベルにおけるペプチドCDMOサービスの売上(消費)、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。(2020~2031)
第4章ペプチドCDMOサービスメーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。(2020~2025)
第5章:ペプチドCDMOサービスの各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。(2020~2031)
第6章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。(2020~2031)
第7章:北米(米国・カナダ):タイプ別、用途別、国別、セグメント別の売上高、収益。(2020~2031)
第8章:ヨーロッパ:タイプ別、用途別、国別、セグメント別の売上高と収益。(2020~2031)
第9章:中国:タイプ別、アプリケーション別、セグメント別の売上高、収益。(2020~2031)
第10章:アジア(中国を除く):タイプ別、用途別、地域別、セグメント別の売上高、収益。(2020~2031)
第11章:中東、アフリカ、中南米:タイプ別、用途別、国別、セグメント別の売上高、収益。(2020~2031)
第12章:ペプチドCDMOサービスの主要メーカーの概要を提供し、製品の説明と仕様、ペプチドCDMOサービスの売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。(2020~2025)
第13章:産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章:ペプチドCDMOサービスの市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章:レポートの要点と結論。
概要
Valued at US$ 4805 million in 2024, the global Peptide CDMO Services market is forecast to reach US$ 11090 million by 2030, at a CAGR of 15.0% during the forecast period. Peptide CDMO Services refer to the specialized contract development and manufacturing services offered by third-party organizations to assist pharmaceutical companies in the production of peptide-based therapeutics. These services typically include peptide synthesis, purification, formulation, and analytical testing to ensure that the peptides meet required quality, purity, and stability standards. CDMOs in this sector provide the expertise and infrastructure needed for large-scale production, offering cost-effective solutions and faster time-to-market for peptide drugs. With the growing demand for personalized medicines and the increasing role of peptides in treating various diseases, including cancer, diabetes, and neurological disorders, peptide CDMOs play a crucial role in the development and manufacturing of peptide therapeutics. The demand for Peptide CDMO (Contract Development and Manufacturing Organization) services is driven by the growing focus on peptide-based therapeutics in the pharmaceutical industry. Peptides are becoming increasingly important in treating a wide range of diseases, including cancer, endocrine disorders, neurological conditions, and autoimmune diseases, due to their ability to offer high specificity, targeted delivery, and fewer side effects compared to traditional small molecules. As the complexity of peptide drugs increases, pharmaceutical companies are increasingly outsourcing the development and manufacturing of these drugs to Peptide CDMOs, which offer specialized expertise, advanced technologies, and scalable production capabilities. This trend is amplified by the rise in biopharmaceutical outsourcing, with companies looking to reduce time-to-market and costs while focusing on their core competencies in research and development.Despite the growing demand for peptide CDMO services, the market faces challenges related to the complexity and cost of peptide synthesis and manufacturing. Peptides often require specialized technologies for synthesis, purification, and formulation, which can make the process both expensive and time-consuming. The production of high-quality peptides at large scale involves significant technical hurdles, such as ensuring purity, stability, and yield, which increases operational costs for CDMOs. Additionally, regulatory hurdles pose a challenge, as peptides often require more stringent oversight compared to traditional drugs. This includes the need for comprehensive documentation, clinical trials, and compliance with GMP (Good Manufacturing Practices). These factors may limit the ability of some smaller CDMOs to compete effectively, making it difficult for them to meet the increasing demand while ensuring high-quality standards.. Report Includes This report presents an overview of global market for Peptide CDMO Services market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. This report researches the key producers of Peptide CDMO Services, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Peptide CDMO Services, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries. This report focuses on the Peptide CDMO Services revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Peptide CDMO Services market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way. This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Peptide CDMO Services revenue, projected growth trends, production technology, application and end-user industry. Descriptive company profiles of the major global players, including Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, etc. Market Segmentation By Company Bachem PolyPeptide CordenPharma AmbioPharm USV Peptides Thermofischer Bio Basic JPT Genscript Xinbang Pharma ScinoPharm SN Biopharm CBL Piramal Pharma CPC Scientific Segment by Type APIs and Intermediates FDF Segment by Application Commercial Academic Research Other By Region North America United States Canada Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Europe Germany France U.K. Italy Russia Nordic Countries Rest of Europe Latin America Mexico Brazil Rest of South America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA Chapter Outline Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term. Chapter 2: Revenue of Peptide CDMO Services in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry. Chapter 3: Detailed analysis of Peptide CDMO Services companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc. Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment. Chapter 7: Europe by Type, by Application and by country, revenue for each segment. Chapter 8: China by Type, and by Application, revenue for each segment. Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment. Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment. Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide CDMO Services revenue, gross margin, and recent development, etc. Chapter 12: Analyst's Viewpoints/Conclusions
総目録
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide CDMO Services Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 APIs and Intermediates
1.2.3 FDF
1.3 Market by Application
1.3.1 Global Peptide CDMO Services Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Commercial
1.3.3 Academic Research
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide CDMO Services Market Perspective (2020-2031)
2.2 Global Peptide CDMO Services Growth Trends by Region
2.2.1 Global Peptide CDMO Services Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Peptide CDMO Services Market Size by Region (2020-2031)
2.3 Peptide CDMO Services Market Dynamics
2.3.1 Peptide CDMO Services Industry Trends
2.3.2 Peptide CDMO Services Market Drivers
2.3.3 Peptide CDMO Services Market Challenges
2.3.4 Peptide CDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Peptide CDMO Services by Players
3.1.1 Global Peptide CDMO Services Revenue by Players (2020-2025)
3.1.2 Global Peptide CDMO Services Revenue Market Share by Players (2020-2025)
3.2 Global Peptide CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Peptide CDMO Services, Ranking by Revenue, 2023 VS 2024 VS 2025
3.4 Global Market Concentration Ratio
3.4.1 Global Peptide CDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide CDMO Services Revenue in 2024
3.5 Global Key Players of Peptide CDMO Services Head office and Area Served
3.6 Global Key Players of Peptide CDMO Services, Product and Application
3.7 Global Key Players of Peptide CDMO Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type
4.1 Global Peptide CDMO Services Historic Market Size by Type (2020-2025)
4.2 Global Peptide CDMO Services Forecasted Market Size by Type (2026-2031)
5 Breakdown Data by Application
5.1 Global Peptide CDMO Services Historic Market Size by Application (2020-2025)
5.2 Global Peptide CDMO Services Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Peptide CDMO Services Market Size (2020-2031)
6.2 North America Market Size by Type
6.2.1 North America Peptide CDMO Services Market Size by Type (2020-2031)
6.2.2 North America Peptide CDMO Services Market Share by Type (2020-2031)
6.3 North America Market Size by Application
6.3.1 North America Peptide CDMO Services Market Size by Application (2020-2031)
6.3.2 North America Peptide CDMO Services Market Share by Application (2020-2031)
6.4 North America Market Size by Country
6.4.1 North America Peptide CDMO Services Market Size by Country: 2020 VS 2024 VS 2031
6.4.2 North America Peptide CDMO Services Market Size by Country (2020-2031)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Peptide CDMO Services Market Size (2020-2031)
7.2 Europe Market Size by Type
7.2.1 Europe Peptide CDMO Services Market Size by Type (2020-2031)
7.2.2 Europe Peptide CDMO Services Market Share by Type (2020-2031)
7.3 Europe Market Size by Application
7.3.1 Europe Peptide CDMO Services Market Size by Application (2020-2031)
7.3.2 Europe Peptide CDMO Services Market Share by Application (2020-2031)
7.4 Europe Market Size by Country
7.4.1 Europe Peptide CDMO Services Market Size by Country: 2020 VS 2024 VS 2031
7.4.2 Europe Peptide CDMO Services Market Size by Country (2020-2025)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Peptide CDMO Services Market Size (2020-2031)
8.2 China Market Size by Type
8.2.1 China Peptide CDMO Services Market Size by Type (2020-2031)
8.2.2 China Peptide CDMO Services Market Share by Type (2020-2031)
8.3 China Market Size by Application
8.3.1 China Peptide CDMO Services Market Size by Application (2020-2031)
8.3.2 China Peptide CDMO Services Market Share by Application (2020-2031)
9 Asia (excluding China)
9.1 Asia Peptide CDMO Services Market Size (2020-2031)
9.2 Asia Market Size by Type
9.2.1 Asia Peptide CDMO Services Market Size by Type (2020-2031)
9.2.2 Asia Peptide CDMO Services Market Share by Type (2020-2031)
9.3 Asia Market Size by Application
9.3.1 Asia Peptide CDMO Services Market Size by Application (2020-2031)
9.3.2 Asia Peptide CDMO Services Market Share by Application (2020-2031)
9.4 Asia Market Size by Region
9.4.1 Asia Peptide CDMO Services Market Size by Region: 2020 VS 2024 VS 2031
9.4.2 Asia Peptide CDMO Services Market Size by Region (2020-2031)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
9.4.8 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Peptide CDMO Services Market Size (2020-2031)
10.2 Middle East, Africa, and Latin America Market Size by Type
10.2.1 Middle East, Africa, and Latin America Peptide CDMO Services Market Size by Type (2020-2031)
10.2.2 Middle East, Africa, and Latin America Peptide CDMO Services Market Share by Type (2020-2031)
10.3 Middle East, Africa, and Latin America Market Size by Application
10.3.1 Middle East, Africa, and Latin America Peptide CDMO Services Market Size by Application (2020-2031)
10.3.2 Middle East, Africa, and Latin America Market Share by Application (2020-2031)
10.4 Middle East, Africa, and Latin America Market Size by Country
10.4.1 Middle East, Africa, and Latin America Peptide CDMO Services Market Size by Country: 2020 VS 2024 VS 2031
10.4.2 Middle East, Africa, and Latin America Peptide CDMO Services Market Size by Country (2020-2031)
10.4.3 Brazil
10.4.4 Mexico
10.4.5 Turkey
10.4.6 Saudi Arabia
10.4.7 Israel
10.4.8 GCC Countries
11 Key Players Profiles
11.1 Bachem
11.1.1 Bachem Company Details
11.1.2 Bachem Business Overview
11.1.3 Bachem Peptide CDMO Services Introduction
11.1.4 Bachem Revenue in Peptide CDMO Services Business (2020-2025)
11.1.5 Bachem Recent Development
11.2 PolyPeptide
11.2.1 PolyPeptide Company Details
11.2.2 PolyPeptide Business Overview
11.2.3 PolyPeptide Peptide CDMO Services Introduction
11.2.4 PolyPeptide Revenue in Peptide CDMO Services Business (2020-2025)
11.2.5 PolyPeptide Recent Development
11.3 CordenPharma
11.3.1 CordenPharma Company Details
11.3.2 CordenPharma Business Overview
11.3.3 CordenPharma Peptide CDMO Services Introduction
11.3.4 CordenPharma Revenue in Peptide CDMO Services Business (2020-2025)
11.3.5 CordenPharma Recent Development
11.4 AmbioPharm
11.4.1 AmbioPharm Company Details
11.4.2 AmbioPharm Business Overview
11.4.3 AmbioPharm Peptide CDMO Services Introduction
11.4.4 AmbioPharm Revenue in Peptide CDMO Services Business (2020-2025)
11.4.5 AmbioPharm Recent Development
11.5 USV Peptides
11.5.1 USV Peptides Company Details
11.5.2 USV Peptides Business Overview
11.5.3 USV Peptides Peptide CDMO Services Introduction
11.5.4 USV Peptides Revenue in Peptide CDMO Services Business (2020-2025)
11.5.5 USV Peptides Recent Development
11.6 Thermofischer
11.6.1 Thermofischer Company Details
11.6.2 Thermofischer Business Overview
11.6.3 Thermofischer Peptide CDMO Services Introduction
11.6.4 Thermofischer Revenue in Peptide CDMO Services Business (2020-2025)
11.6.5 Thermofischer Recent Development
11.7 Bio Basic
11.7.1 Bio Basic Company Details
11.7.2 Bio Basic Business Overview
11.7.3 Bio Basic Peptide CDMO Services Introduction
11.7.4 Bio Basic Revenue in Peptide CDMO Services Business (2020-2025)
11.7.5 Bio Basic Recent Development
11.8 JPT
11.8.1 JPT Company Details
11.8.2 JPT Business Overview
11.8.3 JPT Peptide CDMO Services Introduction
11.8.4 JPT Revenue in Peptide CDMO Services Business (2020-2025)
11.8.5 JPT Recent Development
11.9 Genscript
11.9.1 Genscript Company Details
11.9.2 Genscript Business Overview
11.9.3 Genscript Peptide CDMO Services Introduction
11.9.4 Genscript Revenue in Peptide CDMO Services Business (2020-2025)
11.9.5 Genscript Recent Development
11.10 Xinbang Pharma
11.10.1 Xinbang Pharma Company Details
11.10.2 Xinbang Pharma Business Overview
11.10.3 Xinbang Pharma Peptide CDMO Services Introduction
11.10.4 Xinbang Pharma Revenue in Peptide CDMO Services Business (2020-2025)
11.10.5 Xinbang Pharma Recent Development
11.11 ScinoPharm
11.11.1 ScinoPharm Company Details
11.11.2 ScinoPharm Business Overview
11.11.3 ScinoPharm Peptide CDMO Services Introduction
11.11.4 ScinoPharm Revenue in Peptide CDMO Services Business (2020-2025)
11.11.5 ScinoPharm Recent Development
11.12 SN Biopharm
11.12.1 SN Biopharm Company Details
11.12.2 SN Biopharm Business Overview
11.12.3 SN Biopharm Peptide CDMO Services Introduction
11.12.4 SN Biopharm Revenue in Peptide CDMO Services Business (2020-2025)
11.12.5 SN Biopharm Recent Development
11.13 CBL
11.13.1 CBL Company Details
11.13.2 CBL Business Overview
11.13.3 CBL Peptide CDMO Services Introduction
11.13.4 CBL Revenue in Peptide CDMO Services Business (2020-2025)
11.13.5 CBL Recent Development
11.14 Piramal Pharma
11.14.1 Piramal Pharma Company Details
11.14.2 Piramal Pharma Business Overview
11.14.3 Piramal Pharma Peptide CDMO Services Introduction
11.14.4 Piramal Pharma Revenue in Peptide CDMO Services Business (2020-2025)
11.14.5 Piramal Pharma Recent Development
11.15 CPC Scientific
11.15.1 CPC Scientific Company Details
11.15.2 CPC Scientific Business Overview
11.15.3 CPC Scientific Peptide CDMO Services Introduction
11.15.4 CPC Scientific Revenue in Peptide CDMO Services Business (2020-2025)
11.15.5 CPC Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
表と図のリスト
List of Tables Table 1. Global Peptide CDMO Services Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031 Table 2. Key Players of APIs and Intermediates Table 3. Key Players of FDF Table 4. Global Peptide CDMO Services Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031 Table 5. Global Peptide CDMO Services Market Size Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031 Table 6. Global Market Size by Region (2020-2031) & (US$ Million) Table 7. Global Peptide CDMO Services Market Share by Region (2020-2031) Table 8. Market Trends Table 9. Market Drivers Table 10. Market Challenges Table 11. Market Restraints Table 12. Global Peptide CDMO Services Revenue by Players (2020-2025) & (US$ Million) Table 13. Global Peptide CDMO Services Market Share by Players (2020-2025) Table 14. Global Top Peptide CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO Services as of 2024) Table 15. Global Peptide CDMO Services Industry Ranking 2023 VS 2024 Table 16. Global 5 Largest Players Market Share by Peptide CDMO Services Revenue (CR5 and HHI) & (2020-2025) Table 17. Global Key Players of Peptide CDMO Services, Headquarters and Area Served Table 18. Global Key Players of Peptide CDMO Services, Product and Application Table 19. Global Key Players of Peptide CDMO Services, Date of Enter into This Industry Table 20. Mergers & Acquisitions, Expansion Plans Table 21. Global Market Size by Type (2020-2025) & (US$ Million) Table 22. Global Peptide CDMO Services Revenue Market Share by Type (2020-2025) Table 23. Global Forecasted Market Size by Type (2026-2031) & (US$ Million) Table 24. Global Peptide CDMO Services Revenue Market Share by Type (2026-2031) Table 25. Global Market Size by Application (2020-2025) & (US$ Million) Table 26. Global Peptide CDMO Services Revenue Market Share by Application (2020-2025) Table 27. Global Forecasted Market Size by Application (2026-2031) & (US$ Million) Table 28. Global Peptide CDMO Services Revenue Market Share by Application (2026-2031) Table 29. North America Market Size by Type (2020-2031) & (US$ Million) Table 30. North America Market Size by Application (2020-2031) & (US$ Million) Table 31. North America Peptide CDMO Services Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031 Table 32. North America Market Size by Country (2020-2031) & (US$ Million) Table 33. Europe Market Size by Type (2020-2031) & (US$ Million) Table 34. Europe Market Size by Application (2020-2031) & (US$ Million) Table 35. Europe Peptide CDMO Services Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031 Table 36. Europe Market Size by Country (2020-2025) & (US$ Million) Table 37. China Market Size by Type (2020-2031) & (US$ Million) Table 38. China Market Size by Application (2020-2031) & (US$ Million) Table 39. Asia Market Size by Type (2020-2031) & (US$ Million) Table 40. Asia Market Size by Application (2020-2025) & (US$ Million) Table 41. Asia Peptide CDMO Services Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031 Table 42. Asia Market Size by Region (2020-2031) & (US$ Million) Table 43. Middle East, Africa, and Latin America Market Size by Type (2020-2031) & (US$ Million) Table 44. Middle East, Africa, and Latin America Market Size by Application (2020-2031) & (US$ Million) Table 45. Middle East, Africa, and Latin America Peptide CDMO Services Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031 Table 46. Middle East, Africa, and Latin America Market Size by Country (2020-2031) & (US$ Million) Table 47. Bachem Company Details Table 48. Bachem Business Overview Table 49. Bachem Peptide CDMO Services Product Table 50. Bachem Revenue (2020-2025) & (US$ Million) Table 51. Bachem Recent Development Table 52. PolyPeptide Company Details Table 53. PolyPeptide Business Overview Table 54. PolyPeptide Peptide CDMO Services Product Table 55. PolyPeptide Revenue (2020-2025) & (US$ Million) Table 56. PolyPeptide Recent Development Table 57. CordenPharma Company Details Table 58. CordenPharma Business Overview Table 59. CordenPharma Peptide CDMO Services Product Table 60. CordenPharma Revenue (2020-2025) & (US$ Million) Table 61. CordenPharma Recent Development Table 62. AmbioPharm Company Details Table 63. AmbioPharm Business Overview Table 64. AmbioPharm Peptide CDMO Services Product Table 65. AmbioPharm Revenue (2020-2025) & (US$ Million) Table 66. AmbioPharm Recent Development Table 67. USV Peptides Company Details Table 68. USV Peptides Business Overview Table 69. USV Peptides Peptide CDMO Services Product Table 70. USV Peptides Revenue (2020-2025) & (US$ Million) Table 71. USV Peptides Recent Development Table 72. Thermofischer Company Details Table 73. Thermofischer Business Overview Table 74. Thermofischer Peptide CDMO Services Product Table 75. Thermofischer Revenue (2020-2025) & (US$ Million) Table 76. Thermofischer Recent Development Table 77. Bio Basic Company Details Table 78. Bio Basic Business Overview Table 79. Bio Basic Peptide CDMO Services Product Table 80. Bio Basic Revenue (2020-2025) & (US$ Million) Table 81. Bio Basic Recent Development Table 82. JPT Company Details Table 83. JPT Business Overview Table 84. JPT Peptide CDMO Services Product Table 85. JPT Revenue (2020-2025) & (US$ Million) Table 86. JPT Recent Development Table 87. Genscript Company Details Table 88. Genscript Business Overview Table 89. Genscript Peptide CDMO Services Product Table 90. Genscript Revenue (2020-2025) & (US$ Million) Table 91. Genscript Recent Development Table 92. Xinbang Pharma Company Details Table 93. Xinbang Pharma Business Overview Table 94. Xinbang Pharma Peptide CDMO Services Product Table 95. Xinbang Pharma Revenue (2020-2025) & (US$ Million) Table 96. Xinbang Pharma Recent Development Table 97. ScinoPharm Company Details Table 98. ScinoPharm Business Overview Table 99. ScinoPharm Peptide CDMO Services Product Table 100. ScinoPharm Revenue (2020-2025) & (US$ Million) Table 101. ScinoPharm Recent Development Table 102. SN Biopharm Company Details Table 103. SN Biopharm Business Overview Table 104. SN Biopharm Peptide CDMO Services Product Table 105. SN Biopharm Revenue (2020-2025) & (US$ Million) Table 106. SN Biopharm Recent Development Table 107. CBL Company Details Table 108. CBL Business Overview Table 109. CBL Peptide CDMO Services Product Table 110. CBL Revenue (2020-2025) & (US$ Million) Table 111. CBL Recent Development Table 112. Piramal Pharma Company Details Table 113. Piramal Pharma Business Overview Table 114. Piramal Pharma Peptide CDMO Services Product Table 115. Piramal Pharma Revenue (2020-2025) & (US$ Million) Table 116. Piramal Pharma Recent Development Table 117. CPC Scientific Company Details Table 118. CPC Scientific Business Overview Table 119. CPC Scientific Peptide CDMO Services Product Table 120. CPC Scientific Revenue (2020-2025) & (US$ Million) Table 121. CPC Scientific Recent Development Table 122. Research Programs/Design for This Report Table 123. Key Data Information from Secondary Sources Table 124. Key Data Information from Primary Sources List of Figures Figure 1. Global Peptide CDMO Services Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million) Figure 2. Global Peptide CDMO Services Market Share by Type: 2024 VS 2031 Figure 3. APIs and Intermediates Features Figure 4. FDF Features Figure 5. Global Peptide CDMO Services Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million) Figure 6. Global Peptide CDMO Services Market Share by Application: 2024 VS 2031 Figure 7. Commercial Case Studies Figure 8. Academic Research Case Studies Figure 9. Other Case Studies Figure 10. Peptide CDMO Services Report Years Considered Figure 11. Global Peptide CDMO Services Market Size (US$ Million), Year-over-Year: 2020-2031 Figure 12. Global Peptide CDMO Services Market Size, (US$ Million), 2020 VS 2024 VS 2031 Figure 13. Global Peptide CDMO Services Market Share by Region: 2024 VS 2031 Figure 14. Global Peptide CDMO Services Market Share by Players in 2024 Figure 15. Global Top Peptide CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO Services as of 2024) Figure 16. The Top 10 and 5 Players Market Share by Peptide CDMO Services Revenue in 2024 Figure 17. North America Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 18. North America Peptide CDMO Services Market Share by Type (2020-2031) Figure 19. North America Peptide CDMO Services Market Share by Application (2020-2031) Figure 20. North America Peptide CDMO Services Market Share by Country (2020-2031) Figure 21. United States Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 22. Canada Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 23. Europe Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 24. Europe Peptide CDMO Services Market Share by Type (2020-2031) Figure 25. Europe Peptide CDMO Services Market Share by Application (2020-2031) Figure 26. Europe Peptide CDMO Services Market Share by Country (2020-2031) Figure 27. Germany Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 28. France Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 29. U.K. Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 30. Italy Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 31. Russia Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 32. Nordic Countries Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 33. China Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 34. China Peptide CDMO Services Market Share by Type (2020-2031) Figure 35. China Peptide CDMO Services Market Share by Application (2020-2031) Figure 36. Asia Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 37. Asia Peptide CDMO Services Market Share by Type (2020-2031) Figure 38. Asia Peptide CDMO Services Market Share by Application (2020-2031) Figure 39. Asia Peptide CDMO Services Market Share by Region (2020-2031) Figure 40. Japan Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 41. South Korea Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 42. China Taiwan Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 43. Southeast Asia Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 44. India Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 45. Australia Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 46. Middle East, Africa, and Latin America Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 47. Middle East, Africa, and Latin America Peptide CDMO Services Market Share by Type (2020-2031) Figure 48. Middle East, Africa, and Latin America Peptide CDMO Services Market Share by Application (2020-2031) Figure 49. Middle East, Africa, and Latin America Peptide CDMO Services Market Share by Country (2020-2031) Figure 50. Brazil Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 51. Mexico Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 52. Turkey Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 53. Saudi Arabia Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 54. Israel Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 55. GCC Countries Peptide CDMO Services Market Size YoY Growth (2020-2031) & (US$ Million) Figure 56. Bachem Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 57. PolyPeptide Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 58. CordenPharma Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 59. AmbioPharm Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 60. USV Peptides Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 61. Thermofischer Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 62. Bio Basic Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 63. JPT Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 64. Genscript Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 65. Xinbang Pharma Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 66. ScinoPharm Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 67. SN Biopharm Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 68. CBL Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 69. Piramal Pharma Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 70. CPC Scientific Revenue Growth Rate in Peptide CDMO Services Business (2020-2025) Figure 71. Bottom-up and Top-down Approaches for This Report Figure 72. Data Triangulation Figure 73. Key Executives Interviewed
01. サンプル提供
ご購入前にサンプル(英語、日本語)が提供可能。
02. カスタマイズサービス
レポートの一部をご購入可能;基本バージョンに加え、ご要望に応じたカスタム委託調査も提供可能。
03. プロフェッショナルな日本語翻訳
AI翻訳ではなく、プロフェッショナルな日本語翻訳をご提供。納期:英語は2-4営業日以内、日本語は8-10営業日以内。
04. 多言語コミュニケーション
日本語、英語、中国語、ヒンディー語、ドイツ語、韓国語、フランス語の7ヶ国語でコミュニケーションサービスをご提供。
05. お支払方法
銀行振込(納品後、ご請求書送付)。
06. アフターサービス
ご購入後、ご質問があれば、3ヵ月以内に無料でアナリストと直接的に連絡できる。
請求書払いの場合:
レポート選択
見積もり依頼
メールでのご注文
入手(英語版は2〜4営業日、日本語版は8〜10営業日)
決済(後払い)
クレジットカード決済の場合:
レポート選択
ウェブサイトでのご注文
決済
入手(英語版は2〜4営業日、日本語版は8〜10営業日)